Stuart Therapeutics, Inc. Appoints Dave LeCause as Senior Commercial Advisor

New hire to commercialize a new class of collagen-reparative therapeutics

September 18, 2026
2 min

The Ophthalmologist

Objective:

To announce the appointment of Dave LeCause as senior commercial advisor at Stuart Therapeutics, Inc.

Approach:

Appointment Announcement: Stuart Therapeutics, Inc. has appointed Dave LeCause to lead its commercial strategy as the company advances its lead therapeutic candidate, ST-100 for dry eye disease.

Key Findings:

Dave LeCause will lead the commercial strategy for ST-100, which is expected to begin Phase 3b clinical trials in Q1 2027.
LeCause has a background in executive leadership at Allergan, focusing on eye care products.
His experience includes launching multiple category-defining franchises and building commercial teams.

Interpretation:

LeCause's appointment is seen as a strategic move to enhance the company's commercial capabilities as it prepares to bring its therapeutic platform to market.